(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Sept. 06, 2024 (GLOBE NEWSWIRE) -- The "Digital Marketing Trends in Inflammatory Bowel disease - April 2024" report has been added to ResearchAndMarkets.com's offering.
This report assesses key digital marketing metrics of pharma assets in IBD, including branded websites for patients and HCPs, Unbranded websites, and social media accounts. Metrics include website traffic volume, engagement, and source, DDA, paid SEO, and social media post interaction. Countries include the US, 4EU (Italy, France, Germany, and Spain), the UK, and Canada (EUCAN).
AbbVie's achieved the highest total traffic across inflammatory bowel disease (IBD) patient sites in the US, with over 1.8 million visitors from March 2023 to February 2024. This was followed by AbbVie's with 1.4 million visits. Overall, the highest proportion of traffic to top branded patient IBD websites originated from paid sources, followed by organic sources.
had the highest level of paid traffic (55%), followed closely by (52%). was also supported by the most paid search engine optimization (SEO) at over 6,071 keywords, closely followed by with 5,953 keywords. Takeda spent the most on digital display advertising (DDA) for at approximately $111 million. DDA was also detected for at $14.5 million.
AbbVie's achieved the highest total traffic across IBD healthcare professional (HCP) sites in the US, with over 100,000 visitors from March 2023 to February 2024. achieved 30% of total traffic during this time period. Overall, the highest proportion of traffic to branded IBD websites for HCPs originated from organic sources, followed by paid sources and direct traffic. had the highest proportion of traffic from organic searches (61%), while Cimziahcp.cm had the highest proportion of paid traffic (62%).
Few unbranded IBD sites from pharma were detected in the US, with websites found for just AbbVie and Takeda. AbbVie's had the highest traffic, with almost 69,000 visitors between March 2023 and February 2024. Almost 50% of this traffic was organic, followed by direct traffic at just over 43%.
Abbvie-care.de achieved the highest total traffic across IBD branded sites in the five major European markets (5EU: France, Germany, Italy, Spain, and UK) and Canada (EUCAN), with over 290,000 views from March 2023 to February 2024. No DDA or SEO were detected. Takeda's Ced-trotzdem-ich.de in Italy had the highest traffic across all unbranded IBD sites in EUCAN, with almost 240,000 visitors between March 2023 and February 2024.
This was followed by AbbVie's Leben-mit-ced.de with 195,000 visitors. Overall, the highest proportion of traffic to top unbranded IBD websites originated from organic traffic, followed by direct search. Takeda's Ced-trotzdem-ich.de had the highest proportion of organic traffic (84%), while AbbVie's Leben-mit-ced.de had the most direct traffic (53%). Traffic from social, paid, and referral sources was low.
Reasons to Buy
Understand the digital marketing competitive landscape in IBD, with a view of leading patient and HCP branded assets across different regions. See what tactics pharma companies are using to drive traffic to their IBD branded assets for patient and HCPs, such as DDA and paid SEO. Understand what sources of website traffic are generating the most visits to these assets, such as paid SEO, social media, or organic searches. Compare top branded and unbranded assets for patients by how they address and support different patient needs.
Key Topics Covered:
Executive Summary US Branded Websites for Patients US Branded Websites for Physicians EUCAN Branded Websites EUCAN Unbranded Websites Appendix
For more information about this report visit
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT:
CONTACT:
Laura Wood,Senior Press Manager
...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
MENAFN06092024004107003653ID1108644131
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.